Double maintains 1 strategies that include ALT - Altimmune, Inc.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VGLT | -0.01% | $9.59B | 0.04% |
| LGOV | -0.02% | $664.62M | 0.67% |
| BIV | -0.14% | $23.15B | 0.03% |
| OWNS | -0.18% | $128.37M | 0.3% |
| SPTL | 0.21% | $11.17B | 0.03% |
| ISTB | -0.22% | $4.41B | 0.06% |
| SPIP | 0.23% | $948.26M | 0.12% |
| TLH | 0.23% | $11.30B | 0.15% |
| BUXX | 0.31% | $312.40M | 0.25% |
| JPLD | -0.32% | $2.06B | 0.24% |
| JPST | 0.34% | $31.93B | 0.18% |
| SCHQ | -0.34% | $779.81M | 0.03% |
| SPMB | 0.35% | $6.15B | 0.04% |
| BAB | -0.37% | $924.53M | 0.28% |
| SHV | -0.37% | $20.59B | 0.15% |
| TOTL | -0.40% | $3.80B | 0.55% |
| UITB | 0.41% | $2.33B | 0.39% |
| FLIA | -0.41% | $706.55M | 0.25% |
| TLT | 0.47% | $46.74B | 0.15% |
| BIL | -0.48% | $41.93B | 0.1356% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -27.16% | $184.73M | 0.85% |
| TAIL | -26.65% | $94.86M | 0.59% |
| BTAL | -22.02% | $315.93M | 1.43% |
| IVOL | -17.41% | $342.69M | 1.02% |
| SPTS | -12.35% | $5.77B | 0.03% |
| FXY | -12.32% | $802.69M | 0.4% |
| XONE | -12.20% | $628.85M | 0.03% |
| STPZ | -11.55% | $443.27M | 0.2% |
| ULST | -10.89% | $592.38M | 0.2% |
| CGSM | -10.33% | $716.74M | 0.25% |
| PSQA | -9.81% | $36.49M | 0.2% |
| BILS | -9.59% | $3.80B | 0.1356% |
| UTWO | -9.42% | $376.33M | 0.15% |
| VTIP | -8.68% | $15.15B | 0.03% |
| XHLF | -8.11% | $1.73B | 0.03% |
| UDN | -7.86% | $147.46M | 0.78% |
| VGSH | -7.69% | $22.68B | 0.03% |
| TDTT | -7.68% | $2.63B | 0.18% |
| IBTJ | -7.12% | $686.15M | 0.07% |
| IEI | -7.00% | $15.53B | 0.15% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UNH | 0.04% | $271.70B | -40.62% | 2.85% |
| SAFT | 0.06% | $1.08B | -6.28% | 4.95% |
| ELV | -0.08% | $78.14B | -35.21% | 1.95% |
| OHI | 0.08% | $10.61B | +6.51% | 7.33% |
| SHLS | 0.15% | $966.27M | -9.83% | 0.00% |
| PPC | -0.20% | $10.64B | +33.60% | 0.00% |
| AIFU | 0.25% | $17.40M | +87.81% | 0.00% |
| WMB | 0.33% | $70.55B | +35.41% | 3.38% |
| ZCMD | -0.40% | $28.54M | -8.87% | 0.00% |
| RLX | -0.44% | $2.06B | +24.86% | 0.44% |
| QNRX | 0.47% | $5.30M | -60.39% | 0.00% |
| CNX | -0.51% | $4.82B | +28.19% | 0.00% |
| NOC | -0.53% | $73.96B | +18.95% | 1.66% |
| IMNN | 0.55% | $13.21M | -54.55% | 0.00% |
| ULS | 0.58% | $14.33B | +60.32% | 0.72% |
| NGG | -0.59% | $69.26B | +12.41% | 4.39% |
| FRO | 0.61% | $4.11B | -21.02% | 7.21% |
| SJM | 0.63% | $11.17B | -5.83% | 4.17% |
| GLP | 0.66% | $1.79B | +20.80% | 5.62% |
| CREG | 0.66% | $5.91M | -76.05% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XNCR | 39.65% | $660.47M | -52.14% | 0.00% |
| CLDX | 39.13% | $1.51B | -40.97% | 0.00% |
| CRNX | 38.34% | $3.00B | -39.42% | 0.00% |
| DNLI | 37.41% | $2.23B | -33.52% | 0.00% |
| SDGR | 36.41% | $1.59B | +0.70% | 0.00% |
| VKTX | 36.08% | $3.51B | -46.63% | 0.00% |
| EQIX | 35.89% | $74.23B | -4.88% | 2.40% |
| CDXS | 35.80% | $257.65M | -4.60% | 0.00% |
| ABUS | 35.51% | $628.21M | -6.55% | 0.00% |
| BDTX | 35.31% | $155.80M | -49.17% | 0.00% |
| SLAB | 35.19% | $4.65B | +20.25% | 0.00% |
| LSCC | 35.09% | $7.55B | -6.43% | 0.00% |
| CRSP | 34.95% | $5.10B | +3.85% | 0.00% |
| XPER | 34.95% | $364.13M | -3.39% | 0.00% |
| CRON | 34.54% | $809.38M | -11.76% | 0.00% |
| MEDP | 34.41% | $9.43B | -24.54% | 0.00% |
| SPSC | 34.21% | $5.16B | -29.60% | 0.00% |
| RARE | 34.18% | $2.93B | -29.29% | 0.00% |
| TREX | 34.15% | $6.87B | -18.21% | 0.00% |
| ENTG | 33.98% | $13.32B | -37.43% | 0.46% |
Yahoo
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in the RESTORE Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol-Associated Liver Disease (ALD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist in development f
Finnhub
Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol-Associated Liver Disease ....
Yahoo
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive topline results from its Phase 2b IMPACT trial evaluating Pemvidutide, a treatment candidate for metabolic dysfunction-associated steatohepatitis (MASH). The results mark a key milestone in advancing potential therapies for this chronic liver condition. According to the […]
Finnhub
NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. . Such investors are advised to contact Danielle Peyton at...
Finnhub
Altimmune, Inc. dropped from Russell 3000E Value Index...
Finnhub
Altimmune, Inc. dropped from Russell 3000 Value Index...
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 44.86% | $4.81B | 0.35% |
| PBE | 41.70% | $226.91M | 0.58% |
| IBB | 41.62% | $5.37B | 0.45% |
| GNOM | 41.20% | $46.47M | 0.5% |
| ARKG | 38.91% | $1.03B | 0.75% |
| FBT | 38.43% | $1.02B | 0.54% |
| BBH | 38.06% | $339.54M | 0.35% |
| QQQJ | 37.08% | $625.39M | 0.15% |
| XPH | 37.00% | $150.58M | 0.35% |
| PTH | 36.99% | $96.25M | 0.6% |
| CLOU | 36.69% | $334.66M | 0.68% |
| IWC | 36.28% | $840.86M | 0.6% |
| TECB | 35.79% | $441.13M | 0.3% |
| DUHP | 35.72% | $8.80B | 0.21% |
| IWO | 35.53% | $11.77B | 0.24% |
| KRMA | 35.52% | $651.76M | 0.43% |
| VBK | 35.49% | $19.19B | 0.07% |
| HELO | 35.23% | $3.29B | 0.5% |
| SECT | 35.18% | $2.11B | 0.78% |
| FXL | 35.13% | $1.38B | 0.62% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VOD | -12.63% | $26.61B | +18.72% | 4.50% |
| CIG.C | -11.69% | $2.68B | +23.72% | 0.00% |
| CNC | -11.54% | $16.18B | -51.64% | 0.00% |
| VHC | -10.40% | $69.05M | +176.10% | 0.00% |
| AEP | -9.44% | $56.65B | +16.73% | 3.49% |
| EXC | -9.25% | $44.05B | +23.53% | 3.60% |
| KEP | -9.21% | $17.49B | +85.31% | 0.55% |
| CI | -8.62% | $82.49B | -7.43% | 1.90% |
| TEF | -8.09% | $29.35B | +18.72% | 6.32% |
| RLMD | -7.67% | $22.24M | -84.63% | 0.00% |
| PM | -7.60% | $281.71B | +72.37% | 3.01% |
| K | -7.24% | $27.64B | +40.17% | 2.86% |
| CME | -6.86% | $99.17B | +44.04% | 1.75% |
| VSA | -6.77% | $8.59M | -17.17% | 0.00% |
| MVO | -6.36% | $69.00M | -38.46% | 20.74% |
| NEUE | -6.33% | $60.71M | +34.39% | 0.00% |
| ED | -6.20% | $36.42B | +10.51% | 3.36% |
| DFDV | -5.82% | $363.21M | +2,422.23% | 0.00% |
| LITB | -5.66% | $24.26M | -71.62% | 0.00% |
| CBOE | -5.49% | $24.55B | +38.09% | 1.08% |
Current Value
$4.001 Year Return
Current Value
$4.001 Year Return
